BÜHLMANN Laboratories AG products

BÜHLMANN fPELA® turbo, the turbidimetric immunoassay, is a flexible solution to be applied on most clinical chemistry analyzers. The technology is a milestone in automation of pancreatic elastase quantification. It allows very rapid and flexible random access use, as well as being the ideal solution for high throughput applications in the routine laboratory. The fPELA turbo assay reduces the hands-on time dramatically and allows reporting pancreatic elastase results from human stool samples within shortest time. The CALEX® Cap extraction device is the ideal combination with the BÜHLMANN fPELA® turbo. The extracts are ready to analyse and the CALEX device can be applied directly into the clinical chemistry analyzer. The same extraction buffer for pancreatic elastase AND fecal calprotectin allows the quantitation of both analytes from the same sample preparation.

The Quantum Blue^® Adalimumab assay measures from 1.3 to 35 µg/ml. The target concentrations for the optimal therapeutic window lies well within the linear range of the test. Quantum Blue^® Adalimumab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately while following up the patient’s therapy. Quantum Blue^® Adalimumab is unique in the diagnostics market, being the only test that can provide fast, reliable TDM for adalimumab and it correlates well with the standard routine ELISAs for adalimumab level determinations.

Over the past two decades great improvements in therapy of chronic inflammatory diseases have been made. The rise of TNFα biologics like infliximab has been a significant step forward to ameliorating disease course and keeping inflammations at remission levels for prolonged periods of time. Patients with too low drug concentrations have worse outcomes than those with adequate drug levels. Therapeutic drug monitoring (TDM) for infliximab is an important tool for the management of anti TNF therapy. Patients with undetectable infliximab trough levels may exhibit the presence of anti-drug antibodies (ADA) which can block the effect of the drug. Fast detection of ADA supports guidance in the management of anti TNF therapy for rapid adaptations in the treatment regime.

The Quantum Blue^® Infliximab assay measures from 0.4 to 20 µg/mL. The target concentrations for trough level interpretation lies well within the linear range of the test. Quantum Blue^® Infliximab provides a quantitative result within 15 minutes of incubation time. This offers the possibility to health care providers to act immediately before infusion of the next infliximab dose. Quantum Blue^® Infliximab is unique in the diagnostics market, being the only test that can provide fast, reliable TDM for infliximab and it correlates well with the standard routine ELISAs for infliximab level determinations.

Over the past two decades great improvements in therapy of chronic inflammatory diseases have been made. The rise of anti TNFα biologics has been a significant step forward to ameliorating disease course and keep inflammations at remission levels for prolonged periods of time. Adalimumab is the first anti TNFα biologic on the market approved for patient self-administration by subcutaneous injections. Patients with suboptimal drug concentrations have worse outcomes than those with adequate drug levels.  Therapeutic drug monitoring (TDM) for adalimumab has a great potential for the management of anti TNF therapy. Patients with subtherapeutic or undetectable drug trough levels may exhibit the presence of anti-drug antibodies (ADA) which diminish the clinically beneficial effect of the drug. Fast detection of ADA supports guidance in the management of anti TNF therapy and allows for rapid adaptations in the treatment regime.